Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C17H28N2O |
| Molecular Weight | 276.417 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C
InChI
InChIKey=VTUSIVBDOCDNHS-UHFFFAOYSA-N
InChI=1S/C17H28N2O/c1-6-12-19(8-3)15(7-2)17(20)18-16-13(4)10-9-11-14(16)5/h9-11,15H,6-8,12H2,1-5H3,(H,18,20)
DescriptionCurator's Comment: description was created based on several sources, including
http://www.kiessig.com/drugs/druginfo.aspx?id=1218 | http://www.kiessig.com/drugs/druginfo.aspx?id=1218 | https://www.ncbi.nlm.nih.gov/pubmed/8799190 | https://www.ncbi.nlm.nih.gov/pubmed/8085162
Curator's Comment: description was created based on several sources, including
http://www.kiessig.com/drugs/druginfo.aspx?id=1218 | http://www.kiessig.com/drugs/druginfo.aspx?id=1218 | https://www.ncbi.nlm.nih.gov/pubmed/8799190 | https://www.ncbi.nlm.nih.gov/pubmed/8085162
Etidocaine, marketed under the trade name Duranest, is a local anesthetic given by injection during surgical procedures and labor and delivery. Etidocaine has a long duration of activity, and the main disadvantage of using during dentistry is increased bleeding during surgery. Etidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4187 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | DURANEST Approved UseINDICATIONS AND USAGE. Duranest (Etidocaine HCl) Injections are indicated for infiltration anesthesia, peripheral nerve blocks (e.g., brachial plexus, intercostal, retrobulbar, ulnar, inferior alveolar), and central neural block (i.e., lumbar or caudal epidural blocks). Launch Date1976 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
12.5 μg/mL |
20 mL single, peridural dose: 20 mL route of administration: Peridural experiment type: SINGLE co-administered: EPINEPHRINE |
ETIDOCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.8 μg × h/mL |
20 mL single, peridural dose: 20 mL route of administration: Peridural experiment type: SINGLE co-administered: EPINEPHRINE |
ETIDOCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.7 h |
20 mL single, peridural dose: 20 mL route of administration: Peridural experiment type: SINGLE co-administered: EPINEPHRINE |
ETIDOCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6% |
20 mL single, peridural dose: 20 mL route of administration: Peridural experiment type: SINGLE co-administered: EPINEPHRINE |
ETIDOCAINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Relation of etidocaine and bupivacaine toxicity to rate of infusion in rhesus monkeys. | 1977 Feb |
|
| Central-nervous-system toxicity of local anesthetic mixtures in monkeys. | 1977 Mar |
|
| Comparative CNS toxicity of lidocaine, etidocaine, bupivacaine, and tetracaine in awake dogs following rapid intravenous administration. | 1983 Apr |
|
| Comparison of pain associated with intradermal and subcutaneous infiltration with various local anesthetic solutions. | 1987 Nov |
|
| Alterations in the pharmacokinetic properties of amide local anaesthetics following local anaesthetic induced convulsions. | 1988 Oct |
|
| Relative neural toxicity of local anesthetics. | 1993 May |
|
| Pain of injection and duration of anesthesia for intradermal infiltration of lidocaine, bupivacaine, and etidocaine. | 1994 Jul |
|
| Molecular determinants of state-dependent block of Na+ channels by local anesthetics. | 1994 Sep 16 |
|
| Toxic systemic reactions of bupivacaine and etidocaine. | 1995 Jan |
|
| Cardiac toxicity of local anesthetics in the intact isolated heart model: a review. | 2002 Nov-Dec |
|
| Block of voltage-operated sodium channels by 2,6-dimethylphenol, a structural analogue of lidocaine's aromatic tail. | 2002 Sep |
|
| Cyclic metabolites: chemical and biological considerations. | 2008 Feb |
|
| Complications and controversies of regional anaesthesia: a review. | 2009 Oct |
|
| Direct vasocontractile activities of bupivacaine enantiomers on the isolated rat thoracic aorta. | 2010 |
|
| Advances in labor analgesia. | 2010 Aug 9 |
|
| Progress in analgesia for labor: focus on neuraxial blocks. | 2010 Aug 9 |
|
| Cardiogenic shock associated with loco-regional anesthesia rescued with left ventricular assist device implantation. | 2010 Dec 8 |
|
| The efficacy of ilioinguinal and iliohypogastric nerve block for postoperative pain after caesarean section. | 2010 Jan |
|
| The effects of volatile induction and maintenance of anesthesia and selective spinal anesthesia on QT interval, QT dispersion, and arrhythmia incidence. | 2010 Jun |
|
| Intravenous lipid emulsion in clinical toxicology. | 2010 Oct 5 |
|
| Anesthesia for cataract surgery: Recent trends. | 2010 Sep |
|
| Circadian effects on neural blockade of intrathecal hyperbaric bupivacaine. | 2010 Sep |
Patents
Sample Use Guides
The maximum dose to be employed as a single injection should be determined on the basis of the status of the patient and the type of regional anesthetic technique to be performed. Although single injections of 450 mg have been employed for regional anesthesia without adverse effects, at present it is strongly recommended that the maximal dose as a single injection should not exceed 400 mg (approximately 8.0 mg/kg or 3.6 mg/lb based on a 50 kg person) with epinephrine 1:200,000 and 300 mg (approximately 6 mg/kg or 2.7 mg/lb based on a 50 kg person) without epinephrine.
Route of Administration:
Intramuscular
Rat brain type IIA Na+ channels expressed in Xenopus oocytes were stimulated infrequently (1 pulse per 20 s, all currents were elicited by 15-ms pulses to 0 mV.) This tonic block mainly reflects drug binding to resting channels, the channel state that predominated at the holding potential of -90 mV. Etidocaine (200 mkM) decrease activities of WT Type IIA Na+ channels on ~40%.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
K9D2CE52PU
Created by
admin on Sat Dec 16 11:13:09 GMT 2023 , Edited by admin on Sat Dec 16 11:13:09 GMT 2023
|
PRIMARY | |||
|
38188-41-9
Created by
admin on Sat Dec 16 11:13:09 GMT 2023 , Edited by admin on Sat Dec 16 11:13:09 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
